{"id":724674,"date":"2023-01-19T19:03:07","date_gmt":"2023-01-20T00:03:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/"},"modified":"2023-01-19T19:03:07","modified_gmt":"2023-01-20T00:03:07","slug":"abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/","title":{"rendered":"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent"},"content":{"rendered":"

<\/p>\n

AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent<\/b><\/p>\n

PTAB rejects third request by Berkeley Lights for invalidation of AbCellera\u2019s U.S. patents<\/i><\/p>\n

VANCOUVER, British Columbia–(BUSINESS WIRE<\/a>)–AbCellera<\/a> (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office\u2019s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes<\/i> Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera\u2019s U.S. Patent No. 10,087,408 (the \u2018408 Patent). AbCellera\u2019s \u2018408 Patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells.\n<\/p>\n

\nThe IPR proceeding stems from AbCellera and the University of British Columbia (UBC) suing Berkeley Lights for patent infringement currently pending in the United States District Court for the Northern District of California. In response to AbCellera\u2019s infringement claims, Berkeley Lights filed three separate petitions with the PTAB seeking to invalidate multiple patents. The PTAB previously rejected two of Berkeley Lights\u2019 petitions, disagreeing that certain challenged claims were invalid. Berkeley Lights challenged the claims of the \u2018408 Patent alleging invalidity based on anticipation and obviousness over the prior art. In response to claims against the \u2018408 patent, AbCellera and UBC opposed institution and after oral argument, the PTAB rejected all of Berkeley Lights\u2019 arguments and confirmed that all claims of AbCellera\u2019s \u2018408 Patent are valid.\n<\/p>\n

\n\u201cWe are pleased with the PTAB\u2019s decision, which reinforces the validity and strength of our microfluidic cell culture system patent claims,\u201d said Tryn Stimart, JD, Chief Legal and Compliance Officer of AbCellera. \u201cGoing forward, we will continue to vigorously defend our intellectual property portfolio. With the IPR outcomes, AbCellera intends to request that the district court resume its patent infringement cases against Berkeley Lights.\u201d\n<\/p>\n

About AbCellera Biologics Inc.<\/b><\/p>\n

\nAbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com<\/a>.\n<\/p>\n

AbCellera Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management\u2019s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.\n<\/p>\n

\nIn some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.\n<\/p>\n

\nSource: AbCellera Biologics Inc.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230119005918\/en\/<\/a><\/span><\/p>\n

\nMedia: Jessica Yingling, Ph.D.; media@abcellera.com<\/a>, +1(236)521-6774\n<\/p>\n

\nBusiness Development: Murray McCutcheon, Ph.D.; bd@abcellera.com<\/a>, +1(604)559-9005\n<\/p>\n

\nInvestor Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com<\/a>, +1(778)729-9116\n<\/p>\n

KEYWORDS:<\/b> United States North America Canada California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Medical Devices<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent PTAB rejects third request by Berkeley Lights for invalidation of AbCellera\u2019s U.S. patents VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office\u2019s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera\u2019s U.S. Patent No. 10,087,408 (the \u2018408 Patent). AbCellera\u2019s \u2018408 Patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells. The IPR proceeding stems from AbCellera and the University of British Columbia (UBC) suing Berkeley Lights for patent infringement … <\/p>\n

Continue reading “AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-724674","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent PTAB rejects third request by Berkeley Lights for invalidation of AbCellera\u2019s U.S. patents VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office\u2019s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera\u2019s U.S. Patent No. 10,087,408 (the \u2018408 Patent). AbCellera\u2019s \u2018408 Patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells. The IPR proceeding stems from AbCellera and the University of British Columbia (UBC) suing Berkeley Lights for patent infringement … Continue reading "AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-20T00:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent\",\"datePublished\":\"2023-01-20T00:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/\"},\"wordCount\":744,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/\",\"name\":\"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-01-20T00:03:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/","og_locale":"en_US","og_type":"article","og_title":"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent - Market Newsdesk","og_description":"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent PTAB rejects third request by Berkeley Lights for invalidation of AbCellera\u2019s U.S. patents VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office\u2019s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera\u2019s U.S. Patent No. 10,087,408 (the \u2018408 Patent). AbCellera\u2019s \u2018408 Patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells. The IPR proceeding stems from AbCellera and the University of British Columbia (UBC) suing Berkeley Lights for patent infringement … Continue reading \"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-20T00:03:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent","datePublished":"2023-01-20T00:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/"},"wordCount":744,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/","name":"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-01-20T00:03:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230119005918r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-that-the-u-s-patent-trial-and-appeal-board-upholds-microfluidic-cell-culture-patent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=724674"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724674\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=724674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=724674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=724674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}